Search Results

Kane Biotech Inc. announces that it has entered into a worldwide license agreement with I-MED Pharma Inc. (“I-MED Pharma” or “I-MED”) for the DispersinB ® technology.

Telehealth company Henry Meds, known for its commitment to patient-centric care, announced the launch of Compounded Oral Dissolving Tirzepatide Tablets.

MED-EL, a leader in implantable hearing solutions, celebrates together with everyone living with and benefiting from cochlear implants.

Big Pharma has finally gotten its arms around something advocates have wanted for a long time: direct-to-consumer sales. Eli Lilly and Pfizer are leading the way.

ViroCell Biologics announces that John W. Hadden II, Chief Executive Officer, will be presenting at the annual Cell & Gene Meeting on the Med to be held April 9-11 in Rome, Italy.

Ipsen and GENFIT announced full results from the pivotal Phase III ELATIVE® trial, which are being presented in a late-breaking oral session at the American Association for the Study of Liver Diseases and simultaneously published in New England Journal of Medicine.

IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis technology platform to address significant healthcare needs, today announced its PressureSafe™ decision support device has received U.S. Food and Drug Administration (FDA) listing or the indication of pressure injuries.

Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today announced that Paulash Mohsen, Chief Executive Officer, will present at the 2024 Cell and Gene Meeting on the Med on April 10th at 10:45 AM CET in Rome, Italy.